91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Drug pricing and reimbursement constraints are a major concern for the pharmaceutical industry. Companies must consider price and reimbursement across multiple countries, act early in the development cycle and ensure the evidence required to support their commercial strategy is built into their development plans.
-
In this article Rebecca A Rozich, Director, Client Engagement & Medical Strategy at 91黑料 shares how to effectively measure the true impact of campaigns across social media, disease education and marketing initiatives.
-
In this article, Angela Lawrence, Senior Director of RWE, Joe Brown, Principal Medical and Market Research, and Mark McCoy, RPh, MBA, Director Market Access and Reimbursement discuss the challenges of managing high-cost specialty drugs and how they influence self-funded employer benefit plan design and employee access to specialty medications.
-
A drug’s ability to reach the market is essential; however, pharma manufacturers have struggled to meet the increased pressure to demonstrate the value of their drugs, particularly in therapeutic areas over-populated with treatment options. Data surrounding the success and efficacy of a drug are rarely sufficient to convince stakeholders that the drug is worth the investment. , and against this backdrop, .
-
Manpreet Sidhu and Ben Cieply share insights on .
-
An article in examining mistakes made in relation to and strategies to help reduce risks of future mistakes. 91黑料’s (ICER’s impact on payer decision making) whitepaper was referenced in the article.
-
An article in examining mistakes made in relation to and strategies to help reduce risks of future mistakes. 91黑料’s (ICER’s impact on payer decision making) whitepaper was referenced in the article.
-
The requirements for global HTA/reimbursement consideration have changed and are continuing to evolve in response to the current pandemic. This considers how drug sponsors can navigate a path to reimbursement success and market access for drugs that were in development prior to the pandemic.
